Systemic Light Chain Amyloidosis

Monique Minnema; Stefan Schönland

doi:10.1007/978-3-031-44080-9_82

Systemic Light Chain Amyloidosis

Monique Minnema^*, Stefan Schönland

^*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceeding › Chapter › Academic › peer-review

1 Downloads (Pure)

Abstract

Systemic light chain (AL) amyloidosis is a rare protein misfolding and deposition disorder. Clonal plasma cells or rarely B cells produce immunoglobulin light chains with the potential to misfold. Treatment is clone directed with the goal to achieve a complete or at least very good hematological remission. AutoHCT is an option in a selected group of patients. Results from cellular therapies are encouraging and will play an important role in the future.

Original language	English
Title of host publication	The EBMT Handbook
Subtitle of host publication	Hematopoietic Cell Transplantation and Cellular Therapies
Publisher	Springer
Pages	751-755
Number of pages	5
ISBN (Electronic)	9783031440809
ISBN (Print)	9783031440793
DOIs	https://doi.org/10.1007/978-3-031-44080-9_82
Publication status	Published - 11 Apr 2024

Access to Document

10.1007/978-3-031-44080-9_82Licence: CC BY

978-3-031-44080-9_82Final published version, 330 KBLicence: CC BY

Cite this

@inbook{b82c44ef6a034b63a26f9764903968d2,

title = "Systemic Light Chain Amyloidosis",

abstract = "Systemic light chain (AL) amyloidosis is a rare protein misfolding and deposition disorder. Clonal plasma cells or rarely B cells produce immunoglobulin light chains with the potential to misfold. Treatment is clone directed with the goal to achieve a complete or at least very good hematological remission. AutoHCT is an option in a selected group of patients. Results from cellular therapies are encouraging and will play an important role in the future.",

author = "Monique Minnema and Stefan Sch{\"o}nland",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",

year = "2024",

month = apr,

day = "11",

doi = "10.1007/978-3-031-44080-9_82",

language = "English",

isbn = "9783031440793",

pages = "751--755",

booktitle = "The EBMT Handbook",

publisher = "Springer",

}

TY - CHAP

T1 - Systemic Light Chain Amyloidosis

AU - Minnema, Monique

AU - Schönland, Stefan

PY - 2024/4/11

Y1 - 2024/4/11

N2 - Systemic light chain (AL) amyloidosis is a rare protein misfolding and deposition disorder. Clonal plasma cells or rarely B cells produce immunoglobulin light chains with the potential to misfold. Treatment is clone directed with the goal to achieve a complete or at least very good hematological remission. AutoHCT is an option in a selected group of patients. Results from cellular therapies are encouraging and will play an important role in the future.

AB - Systemic light chain (AL) amyloidosis is a rare protein misfolding and deposition disorder. Clonal plasma cells or rarely B cells produce immunoglobulin light chains with the potential to misfold. Treatment is clone directed with the goal to achieve a complete or at least very good hematological remission. AutoHCT is an option in a selected group of patients. Results from cellular therapies are encouraging and will play an important role in the future.

UR - http://www.scopus.com/inward/record.url?scp=85207172748&partnerID=8YFLogxK

U2 - 10.1007/978-3-031-44080-9_82

DO - 10.1007/978-3-031-44080-9_82

M3 - Chapter

AN - SCOPUS:85207172748

SN - 9783031440793

SP - 751

EP - 755

BT - The EBMT Handbook

PB - Springer

ER -

Systemic Light Chain Amyloidosis

Abstract

Access to Document

Other files and links

Fingerprint

Cite this